布拉氏酵母菌散结合美沙拉嗪治疗中轻度溃疡性结肠炎的效果评价

摘要/Abstract

摘要： 目的探讨布拉氏酵母菌散联合美沙拉嗪对中轻度溃疡性结肠炎（UC）的治疗作用。方法选取2021年1~2021年12月敦化市医院收治的中轻度溃疡性结肠炎患者88例,按照随机数表法分组,44例为对照组,给予美沙拉嗪治疗,44例为观察组,给予布拉氏酵母菌散联合美沙拉嗪治疗,比较两组疗效。结果观察组总有效率高于对照组（P<0.05）;治疗后,观察组血清肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-10（IL-10）水平均低于对照组（P<0.05）;治疗后,观察组内镜下评分及相关症状积分均低于对照组（P<0.05）;两组不良反应率比较差异无统计学意义（P>0.05）。结论与对中轻度UC患者实施单独美沙拉嗪治疗相比,布拉氏酵母菌散联合美沙拉嗪治疗总有效率更高,能够明显降低血清炎症因子水平,缓解患者症状,降低内镜下评分,且不良反应较少,安全性较好。

关键词: 溃疡性结肠炎, 布拉氏酵母菌散, 美沙拉嗪

Abstract: Objective To investigate the therapeutic effect of Saccharomyces boulardii powder + Mesalazine on moderate to mild ulcerative colitis (UC). Methods A total of 88 patients with moderate and mild ulcerative colitis admitted to Hospital of Dunhua City from January 2021 to December 2021 were selected. They were divided into groups according to the random number table method. 44 cases in the control group were treated with Mesalazine, and 44 cases in the observation group were treated with Saccharomyces boulardii powder + Mesalazine, the curative effect of two groups were compared. Results Compared with the total effective rate, the observation group was higher than the control group (P<0.05). After treatment, the serum tumor necrosis factor-α (TNF-α), interleukin-6 (interleukin-6, IL-6) and interleukin-10 (interleukin-10, IL-10) levels were lower than those in the control group (P<0.05); The endoscopic score and related symptom scores in the observation group after treatment were lower than those in the control group (P<0.05). There was no significant difference in adverse reaction rate between two groups (P>0.05). Conclusion Compared with Mesalazine alone in patients with moderate to mild UC, the combined treatment of Saccharomyces boulardii powder + Mesalazine is more effective, significantly reduces serum inflammatory factors, relieves symptoms, and reduces endoscopic scores, and fewer adverse reactions and better safety.

Key words: ulcerative colitis, Saccharomyces boulardii powder, mesalazine

中图分类号:

R574.62

霍岩. 布拉氏酵母菌散结合美沙拉嗪治疗中轻度溃疡性结肠炎的效果评价[J]. 中华养生保健, 2023, 41(1): 50-53.

HUO Yan. Efficacy Evaluation of Saccharomyces Boulardii Powder Combined with Mesalazine in the Treatment of Moderate and Mild Ulcerative Colitis[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(1): 50-53.

参考文献

[1] 张莉,顾清,代小松,等.美沙拉嗪联合布拉氏酵母菌散治疗溃疡性结肠炎的疗效及对炎症因子的影响[J].西部医学,2018,30(7):1002-1004,1009.
[2] 赵鑫. 布拉氏酵母菌散联合美沙拉嗪肠溶片治疗溃疡性结肠炎的临床效果分析[J].中国药物与临床,2019,19(3):87-88.
[3] Sohail M, Abbasi M, Minhas M U, et al.Natural and Synthetic Polymers Based Smart Biomaterials for Management of Ulcerative Colitis: A Review of Recent Developments and Future Prospects[J]. Drug Delivery and Translational Research,2018,9(1):1-20.
[4] 中华中医药学会.溃疡性结肠炎诊疗指南[J].中国中医药现代远程教育,2011,9(10):126-128.
[5] 沙吉达·巴吾东.氨基酸奶粉结合布拉氏酵母菌治疗婴儿牛奶诱导直肠结肠炎(过敏性腹泻)的临床分析[J].中国保健营养,2020,30(26):326.
[6] 杨川江,颜玉,姜威,等.益生菌对DSS诱导溃疡性结肠炎小鼠模型TLR-9、NF-κB表达的影响[J].黑龙江医药科学,2018,41(3):69-71.
[7] 赵鑫. 布拉氏酵母菌散联合美沙拉嗪肠溶片治疗溃疡性结肠炎的临床效果分析[J].中国药物与临床,2019,19(3):429-430.
[8] 马静,徐俊丽,冉妮娜,等.布拉氏酵母菌散联合美沙拉嗪肠溶片治疗中轻度溃疡性直乙状结肠炎的疗效观察[J].中国中西医结合消化杂志,2020,28(4):260-263.
[9] Burmester G R, Sands B E, Papp K, et al.Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure[J].RMD Open,2021,7(2):1587-1598.
[10] 王小静. 益生菌和美沙拉嗪治疗轻、中度活动期溃疡性结肠炎的效果及安全性评价[J].母婴世界,2017,(18):103.
[11] 王娟,陈袭,赵赛先.建中化湿汤联合美沙拉嗪及双歧杆菌四联活菌片治疗活动期溃疡性结肠炎患者的效果[J].中国民康医学,2021,33(15):79-81.
[12] Willian M K, D’Haens G, Yarlas A, et al. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study[J]. Journal of Patient-Reported Outcomes,2018,2(1):1-16.
[13] 费香勇. 利湿和血汤辅助美沙拉嗪治疗溃疡性结肠炎疗效及对生活质量、炎症免疫细胞因子水平的影响[J].中国中医急症,2017,26(6):1097-1099.
[14] 张培源,雷雪,张红月,等.美沙拉嗪口服联合灌肠对溃疡性结肠炎患者的疗效及ICAM-1、VCAM-1的影响[J].中国处方药,2022,20(3): 100-102.
[15] Spagnuolo R, Dattilo V, D’Antona L, et al. Deregulation of SGK1 in Ulcerative Colitis: A Paradoxical Relationship Between Immune Cells and Colonic Epithelial Cells[J].Inflammatory Bowel Diseases,2018, 24(9):e71-e72.
[16] 李义安. 美沙拉嗪与双歧杆菌三联活菌散对溃疡性结肠炎患者的临床疗效及其对免疫球蛋白水平和症状改善作用的影响[J].抗感染药学,2018,15(4):641-644.
[17] Archer R, Tappenden P, Ren S, et al.Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model[J]. Health technology assessment (Winchester, England),2016,20(39):326.
[18] 叶惠珍,陈陶甫,徐权胜.安肠愈疡汤联合美沙拉嗪治疗溃疡性结肠炎的疗效及对血清炎症因子水平的影响[J].云南中医中药杂志,2019,40(4):58-59.
[19] 陈婧,张荣,邱昌伟.双歧杆菌三联活菌联合美沙拉嗪治疗溃疡性结肠炎患者的临床效果[J].中外医学研究,2020,18(3):23-24.
[20] 李建军. 美沙拉秦栓联合布拉氏酵母菌散治疗轻中度溃疡性直肠炎疗效观察[J].现代中西医结合杂志,2020,29(20):2241-2244.